Loading
Mosquito Borne Diseases and Control · Journal article
Bangladesh Journal of Infectious Diseases · September 8, 2026
A consensus or society position rather than new primary data.
This is a narrative review of dengue epidemiology, transmission, diagnosis, treatment, and prevention strategies, including discussion of vaccine options (Qdenga and Dengvaxia) and vector control approaches. It synthesizes existing knowledge and provides recommendations for surveillance, vaccination programs, and integrated vector management, but does not constitute primary evidence or meta-analytic synthesis.
Narrative review. Global dengue epidemiology and disease burden; Bangladesh as endemic case study. Global focus; specific emphasis on South Asia, Americas, Southeast Asia, and Bangladesh.
Annual dengue cases globally range from 100 to 400 million, with nearly half the world's population at risk Four serotypes (DENV-1 to DENV-4) each confer lifelong immunity against reinfection by the same serotype but lack cross-immunity Transmission driven by Aedes aegypti and Aedes albopictus in tropical and subtropical regions; incidence increasing due to climate change, urbanization, and inadequate vector control
Comparative efficacy and safety data for Qdenga vs Dengvaxia mentioned but specific figures not provided in abstract Bangladesh 2023 outbreak described qualitatively without case numbers, mortality, or outbreak duration
Clinicians and public health professionals should recognize dengue as an escalating global burden requiring integrated approaches: enhanced diagnostic capability, consideration of vaccine options (Qdenga and Dengvaxia) with attention to population-specific efficacy and safety profiles, and sustained investment in vector control. The endemic transition in Bangladesh exemplifies the need for sustained surveillance and prevention infrastructure.
A comprehensive narrative review synthesizing epidemiology, pathophysiology, diagnostics, treatment, and prevention strategies for dengue; provides expert synthesis and recommendations rather than new primary evidence.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians and public health professionals should recognize dengue as an escalating global burden requiring integrated approaches: enhanced diagnostic capability, consideration of vaccine options (Qdenga and Dengvaxia) with attention to population-specific efficacy and safety profiles, and sustained investment in vector control. The endemic transition in Bangladesh exemplifies the need for sustained surveillance and prevention infrastructure.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Dengue virus (DENV), a mosquito-borne RNA virus of the Flaviviridae family, poses a major global health challenge, with nearly half of the world’s population at risk and annual cases ranging from 100 to 400 million. It is transmitted primarily by Aedes mosquitoes, specifically Aedes aegypti and Aedes albopictus, which thrive in tropical and subtropical regions. The virus consists of four serotypes (DENV-1 to DENV-4), each conferring lifelong immunity against reinfection by the same serotype but lacking cross-immunity. The increasing incidence of dengue outbreaks is driven by climate change, urbanization, and inadequate vector control measures, with regions such as South Asia, the Americas, and Southeast Asia reporting millions of cases annually. This review provides a comprehensive analysis of dengue epidemiology, virus transmission dynamics, replication mechanisms, clinical manifestations, and diagnostic approaches. It also explores recent advancements in vaccine development, particularly the comparison between Qdenga and Dengvaxia, highlighting their differences in efficacy, safety, and target populations. Despite efforts in vaccine research, vector control remains the primary strategy for dengue prevention, focusing on environmental management, biological control, and targeted chemical interventions. The study further examines Bangladesh as a case study, documenting its largest-ever dengue outbreak in 2023 and its transition into an endemic phase in early 2025. The findings underscore the urgent need for enhanced surveillance systems, integrated vector management, and public health initiatives to combat dengue globally. Strengthening diagnostic capabilities, expanding vaccination programs, and investing in innovative mosquito control strategies will be crucial in mitigating the growing burden of dengue worldwide. Bangladesh Journal of Infectious Diseases, June 2026;13(1):397-410
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.